---

Outcome of intravitreal triamcinolone (IVTA) acetonide in various posterior segment disorder

---

Original Article

Author Details : S Kalpana, Sneha Priya Prabhakar, Ara Fauzia*

Volume : 8, Issue : 1, Year : 2022

Article Page : 13-19

https://doi.org/10.18231/j.ijceo.2022.004

Suggest article by email

Get Permission

---

Abstract

Aim: To study the response to the injection of intra-vitreal triamcinolone acetate (IVTA) in various indications and to identify the IOP rise between various groups.
Materials and Methods: An interventional, prospective study was conducted on 50 patients at vitreo-retinal department at tertiary eye hospital in Bangalore in the period of November 2015 to May 2017. Each patient was subjected to a detailed assessment which included patient’s demographic data & detailed history. Best corrected visual-acuity (BCVA), Intra ocular pressure(IOP) was recorded. Macular oedema is confirmed by optical coherence tomography and fluorescein angiography. Patients that received injection IVTA were followed up for 6 months.
Results: The mean age of subjects was 56.78±10.76 years, 54% were males and 46% were females. In the study, 46% of eyes were diagnosed at CSME, 38% as BRVO, 8% as pseudophakic CME, 6% as CRVO and 2% as Uveitis. The mean BCVA LogMAR at baseline was 0.87±0.43 and at 6 months follow up mean BCVA LogMAR was 0.59 ± 0.42. In the study mean IOP at baseline was 14.24±3.01 and at 6 months follow up mean IOP was 15.12 ± 3.60. There was significant increase in IOP at 1 month follow up. The mean central macular thickness (CMT) at baseline was 469.4±138.4 and at 6 months follow up mean CMT was 290.9 ± 140.7.
Conclusion: Although there is a risk of raised IOP, IVTA can be preferred as a modality of treating macular edema as it has good results and is very economical and affordable.
 

Keywords: IVTA, IOP, Macular oedema.

How to cite : Kalpana S, Prabhakar S P, Fauzia A, Outcome of intravitreal triamcinolone (IVTA) acetonide in various posterior segment disorder. Indian J Clin Exp Ophthalmol 2022;8(1):13-19

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.